Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions

In Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions, our panel/experts delve(s) into the following critical questions:

How are you differentiating between the 2 FDA-approved cardiac myosin inhibitors, mavacamten and aficamten?

Do the different pharmacokinetics between the 2 impact your treatment decisions?

Led by Dr. Martin Maron, the Drs. Harper, Rader, and Le discuss differentiation between mavacamten and aficamten, which often centers on their pharmacokinetic profiles, including half-life, time to steady state, and flexibility in dose adjustments. These differences can influence how quickly clinicians can titrate therapy and respond to changes in patient status or adverse effects. Aficamten’s shorter half-life may allow for more rapid dose optimization and potentially easier management in situations requiring interruption, while mavacamten’s longer half-life may require more cautious adjustments. As a result, pharmacokinetics can play an important role in treatment decisions, particularly when considering patient-specific factors such as comorbidities, concomitant medications, and the need for close monitoring.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.